Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: A study of the German Testicular Cancer Study Group

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 448-453

  Bokemeyer, C ^a   Oechsle, K ^a   Honecker, F ^a   Mayer, F ^c   Hartmann, J T ^c   Waller, C F ^d   Bohlke I ^a   Kollmannsberger, C ^b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cisplatin refractory; Gemcitabine; Germ cell tumor; Oxaliplatin; Paclitaxel; Relapsed

Indexed keywords

ANTIEMETIC AGENT; BLEOMYCIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; GEMCITABINE; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; OXALIPLATIN; PACLITAXEL; SEROTONIN 3 ANTAGONIST;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GERM CELL TUMOR; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ADULT; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; TESTICULAR NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 40149109480     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm526     Document Type: Article

References (27)

1. Bosl GJ, Motzer RJ. Medical progress: Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
2. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 2002; 99: 4592-4595.
3. Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ. cell tumors. Cancer 2006; 106: 1217-1226.
4. Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990; 17: 36-39.
5. Motzer RJ, Bajorin D, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-2283.
6. Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996; 7: 31-34.
7. Bokemeyer C, Geri A, Schöffski P et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer, J Clin Oncol 1999; 17: 512-516.
8. Einhom LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors, J Clin Oncol 1999; 17: 509-511.
9. Kollmannsberger C, Rick O, Derigs H-G et al. Activity of oxaliplatin in patients with relapsed or cisplatin-retractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 2002; 20: 2031-2037.
10. Motzer RJ, Mazumdar M, Sheinteld J et al. Sequential dose-intensive paclitaxel, itosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1173-1180.
11. Rick O, Bokemeyer C, Beyer J et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stell cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001; 19: 81-88.
12. Dunn TA, Schmoll HJ, Grünwald V et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell lines. Invest New Drugs 1997; 15: 109-114.
13. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44: 117-123.
14. Kollmannsberger C, Beyer J, Liersch R et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 2004; 22: 108-114.
15. Nichols CR, Tricol G, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989 7: 932-939.
16. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-2645.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trtials 1989; 10: 1-10.
18. Porcu P, Bhatia S, Einhorn LH. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 2000; 18: 1181-1186.
19. Hinton S, Catalano PJ, Einhorn L et al. Phase II trial of paclitaxel and gemcitabine in refractory germ cell tumors. J Clin Oncol 2001; 20: 1859-1863.
20. Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: A phase II study. Eur Urol 2004; 46: 216-221.
21. Pectasides D; Pectasides M, Farmakis D et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: A phase II study. Ann Owol 2004; 15: 493-497.
22. Theodore C, Flechon A, Fizazi K et al, A phase II multicentre study of oxaliplatin (Ox) in combination with paclitaxel (Px) in patients (pts) who failed cisplatin (CDDP) based chemotherapy (CT) for germ cell tumors (GCT). Proc Am Soc Clin Oncol 2004; 23: 389 (Abstr 4534).
23. Miki T, Mizutani Y, Nonomura N et al. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 2002; 95: 1879-1885.
24. De Giorgi U, Rosti G, Aieta M et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur urol 2006; 50: 1032-1038, discussion 1038-1039.
25. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 2007; 25: 513-516.
26. De Giorgi U, Rosti G, Papiani G et al. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor: Preliminary experience. Am J Clin Oncol 2004; 27: 457-460.
27. de Wit R, Louwerens M, de Mulder PHM et al, Management of intermediate prognosis germ cell cancer: Results of a phase I/II study of taxol-BEP. Int J Cancer 1999; 83: 831-833.